Found: 20
Select item for more details and to access through your institution.
New drugs for multiple myeloma.
- Published in:
- Australian Prescriber, 2009, v. 32, n. 4, p. 95, doi. 10.18773/austprescr.2009.047
- By:
- Publication type:
- Article
A costing study of bortezomib shows equivalence of its real‐world costs to conventional treatment.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 3, p. e76, doi. 10.1111/bjh.16484
- By:
- Publication type:
- Article
Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometry‐based proteomics in an Australian cohort.
- Published in:
- Internal Medicine Journal, 2022, v. 52, n. 1, p. 69, doi. 10.1111/imj.15072
- By:
- Publication type:
- Article
Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
- Published in:
- Internal Medicine Journal, 2017, v. 47, n. 8, p. 938, doi. 10.1111/imj.13502
- By:
- Publication type:
- Article
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
- Published in:
- Internal Medicine Journal, 2017, v. 47, n. 1, p. 35, doi. 10.1111/imj.13311
- By:
- Publication type:
- Article
Kutatási tapasztalatok, eredmények Mezőcsát településen.
- Published in:
- Economica (1585-6216), 2014, v. 7, n. 3, p. 149
- By:
- Publication type:
- Article
Bioelectrochemical Systems (BES) for Biomethane Production—Review.
- Published in:
- Fermentation (Basel), 2023, v. 9, n. 7, p. 610, doi. 10.3390/fermentation9070610
- By:
- Publication type:
- Article
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment--An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 8, p. 543, doi. 10.1016/j.clml.2024.04.001
- By:
- Publication type:
- Article
Carfilzomib, Thalidomide and Dexamethasone (KTd) is safe and effective in RRMM: interim analysis of the single arm, multicentre phase II ALLG MM018/AMN002 study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e274, doi. 10.1016/j.clml.2019.09.452
- By:
- Publication type:
- Article
Utilisation of liquid biopsies in functional high-risk myeloma demonstrates a unique mutational pattern and extensive spatial heterogeneity.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e7, doi. 10.1016/j.clml.2019.09.010
- By:
- Publication type:
- Article
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM): A report from the MRDR.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e30, doi. 10.1016/j.clml.2017.03.052
- By:
- Publication type:
- Article
Maturing Data from the Australia and New Zealand Myeloma and Related Diseases Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e105, doi. 10.1016/j.clml.2017.03.190
- By:
- Publication type:
- Article
Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM Based on Prior Lines and Treatment Exposure: CASTOR.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e133, doi. 10.1016/j.clml.2017.03.240
- By:
- Publication type:
- Article
Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00796-9
- By:
- Publication type:
- Article
A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 5, p. 536, doi. 10.1002/ajh.23684
- By:
- Publication type:
- Article
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 10, p. 650, doi. 10.1002/ajh.21509
- By:
- Publication type:
- Article
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.
- Published in:
- BMC Medical Research Methodology, 2016, v. 16, p. 1, doi. 10.1186/s12874-016-0250-z
- By:
- Publication type:
- Article
Consolidation therapy without maintenance for acute non‐lymphoblastic leukaemia.
- Published in:
- Medical Journal of Australia, 1988, v. 148, n. 4, p. 181, doi. 10.5694/j.1326-5377.1988.tb112809.x
- By:
- Publication type:
- Article